Evolving Treatments of Metastatic CRC: Insights from ASCO 2024 - Episode 7

Exploring Data Outcomes From the SUNLIGHT Trial

, , , ,

Leading colorectal cancer specialists analyze the SUNLIGHT trial results, focusing on age-related efficacy data and its implications for treatment strategies.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected
    EP. 1: Overview of Molecular Testing and Barriers in mCRC
    EP. 2: Clinical Considerations for 2L Treatment Sequencing in mCRC
    EP. 3: Novel Combination Regimens for 2L mCRC: Insights from ASCO 202
    EP. 4: Exploring Toxicities for Second Line Treatments in mCRC
    EP. 5: Existing Challenges for Patients Receiving 3L+ Therapies in mCRC
    EP. 6: Factors Driving 3L Therapeutic Selection for mCRC
    Now Viewing
    EP. 7: Exploring Data Outcomes From the SUNLIGHT Trial
    EP. 8: Fruquintinib for mCRC: Data from the FRESCO & FRESCO-2 Studies
    EP. 9: Examining the Evolving 3L Treatment Landscape for mCRC
    EP. 10: Additional Key Takeaways of ASCO 2024 Data in mCR
    EP. 11: Future Outlooks in the Treatment of Metastatic Colorectal Cancer
    1. Briefly summarize the SUNLIGHT trial, evaluating TAS-102 ± bevacizumab in patients with mCRC (Prager, et al. NEJM, 2023)
      1. Dr Fakih: How does age impact efficacy and safety outcomes from the SUNLIGHT trial in mCRC? (Taieb J, et al. ASCO GI 2024. Abstract 111)
      2. Dr Benson: What is the impact of colorectal liver metastases (CRLM) in patients with mCRC treated with TAS-102 ± bevacizumab? (Tabernero J, et al. ASCO 2024. Abstract 3584.)

    x